Search clinical trials for: Angiotensin II Receptor Blockers

Total 2465 results

Takeda

Completed

A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

Hypertension

Japan
Palo Alto Veterans Institute for Research
Medtronic; James Cook University, Queensland, Australia

Completed

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms (TEDY)

Abdominal Aortic Aneurysm

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

Hypertension

United States
Ain Shams University

Completed

Chronopharmacology of Valsartan in Normotensive Subjects

Healthy Normotensive Volunteers

Egypt
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Valsartan

Type 2 Diabetes

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Congestive Heart Failure

Netherlands, Portugal, Spain, United States, Belgium, Italy, Argentina, Brazil, Canada, France, Germany, Mexico, South Africa, Sweden, Australia, Russian Federation, Poland, Czech Republic, Denmark, Ireland, Hungary, Switzerland, Gr... and more
Karin Skov
AstraZeneca; University of Aarhus

Unknown

Danish Hypertension Prevention Project - DHYPP

Hypertension

Denmark
Fundación Cardiovascular de Colombia
AstraZeneca

Terminated

Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects (ARAMIA)

Obesity | Glucose Intolerance

Colombia
Seung-Jung Park
Novartis

Completed

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent (VAL-SUPPRES)

Coronary Artery Disease

Korea, Republic of
Osaka City University

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Non-Hodgkin's Lymphoma

Japan
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
Rambam Health Care Campus

Unknown

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

NIDDM

Israel
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) (ARCADE)

Ehlers-Danlos Syndrome, Vascular Type

France
Boehringer Ingelheim

Completed

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

Hypertension

Belgium, Canada, Colombia, Czechia, Ecuador, Indonesia, Jordan, Lebanon, Mexico, Turkey, Venezuela, Yemen
University of California, Los Angeles
California HIV/AIDS Research Program

Completed

HIV and Fat Accumulation (MATH)

HIV Infection

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

Hypertension

United States
Boehringer Ingelheim

Completed

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

Hypertension
Novartis

Completed

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Proteinuria | Microalbuminuria

Egypt
Novartis

Completed

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Diastolic Dysfunction, Symptomatic Heart Failure

Switzerland, Germany
Kumamoto University

Terminated

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Hypertension

Japan
Boehringer Ingelheim

Completed

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Hypertension
Novartis

Completed

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

Hypertension

Germany
Novartis

Completed

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Hypertension

Switzerland
University of Campania "Luigi Vanvitelli"

Completed

Telmisartan in Haemodialysis Patients With Chronic Heart Failure

Heart Failure, Congestive

Italy
Novartis

Completed

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

Healthy

United States
Novartis

Completed

To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers

Healthy

India
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Essential Hypertension

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The DDI Study of SP2086 and Valsartan

Type 2 Diabetes

China
Takeda

Completed

A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet

Hypertension

Japan
LG Life Sciences

Completed

Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
University of California, Los Angeles
The Campbell Foundation

Completed

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Endothelial Dysfunction

United States
Novartis

Completed

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

Hypertension | Diastolic Dysfunction

United States
Samsung Medical Center

Unknown

The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

Proteinuria | Chronic Kidney Disease

Korea, Republic of
Charles University, Czech Republic
AstraZeneca

Unknown

CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Czech Republic
Asker & Baerum Hospital
Ullevaal University Hospital; AstraZeneca; Helse Ost

Completed

Candesartan in the Prevention of Relapsing Atrial Fibrillation

Atrial Fibrillation

Norway
Karolinska University Hospital
AstraZeneca

Unknown

Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy

Diabetes, Type I

Sweden
The Japanese Society of Hypertension

Unknown

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Cardiovascular Diseases | Hypertension

Japan
Boehringer Ingelheim

Completed

Antihypertensive Medications and the Risk of Sepsis

Hypertension
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Irbesartan

Obesity, Morbid

Norway
Takeda

Completed

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Hypertension

Japan
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Boehringer Ingelheim

Completed

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Hypertension
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Hypertension
Boehringer Ingelheim

Completed

Pharmacovigilance and Patient Compliance in Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

BIBR 277 Capsules in Hypertensive Patients With Nephropathy

Hypertension
AstraZeneca

Completed

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Congestive Heart Failure
Sanofi
Bristol-Myers Squibb

Completed

Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria (PRIME)

Hypertension
Saitama Medical University
Non-Profit Organaizaion "LINE"

Unknown

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

Hypertension

Japan

3

Subscribe